BOSTON, June 16 /PRNewswire/ -- Scimitar Equity, LLC issues a review of VioQuest Pharmaceuticals, Inc. (OTC Bulletin Board: VOQP), entitled, "Robust Pipeline of Niche' Cancer Therapies with Billion Dollar Upside."
This review is available at website: http://www.scimitarequity.com.
VioQuest Pharmaceuticals is a New Jersey-based biotechnology company dedicated to becoming a recognized leader in the successful development of novel drug therapies targeting both the molecular basis of cancer and side effects of treatment. VioQuest's oncology portfolio includes: Xyfid(TM) (1% uracil topical), for the treatment and prevention of Hand-Foot Syndrome, a common side effect from certain chemotherapy treatments, and to treat dry skin conditions and manage the burning and itching associated with various dermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; and Lenocta(TM) (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B. Further information about VioQuest can be found at: http://www.vioquestpharm.com
Scimitar Equity, LLC provides sponsored equity research of emerging
healthcare companies for the investing communities. We certify that all the
views expressed in this review, accurately reflect our personal views about
VioQuest Pharmaceuticals, Inc (OTC Bulletin Board: VOQP) and its or their
securities. No part of our compensation was, is, or will be, directly or
indirectly, related to the specific recommendations or views contained in
this review and we will not have any investment banking relationships or
personal investment in any sponsored company. Investors are advised that
this analysis and review is issued solely for informational purposes and is
not to be construed as an offer to sell or the solicitation of an offer to
|SOURCE Scimitar Equity, LLC|
Copyright©2008 PR Newswire.
All rights reserved